144 related articles for article (PubMed ID: 24243316)
1. Tigecycline pharmacokinetics, tolerability, safety, and effect on intestinal microflora in healthy Japanese male subjects.
Yamashita N; Matschke K; Gandhi A; Korth-Bradley J
J Clin Pharmacol; 2014 May; 54(5):513-9. PubMed ID: 24243316
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.
Muralidharan G; Micalizzi M; Speth J; Raible D; Troy S
Antimicrob Agents Chemother; 2005 Jan; 49(1):220-9. PubMed ID: 15616299
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, safety and tolerability of tigecycline.
Rello J
J Chemother; 2005 Aug; 17 Suppl 1():12-22. PubMed ID: 16285354
[TBL] [Abstract][Full Text] [Related]
4. Effect of tigecycline on normal oropharyngeal and intestinal microflora.
Nord CE; Sillerström E; Wahlund E
Antimicrob Agents Chemother; 2006 Oct; 50(10):3375-80. PubMed ID: 17005820
[TBL] [Abstract][Full Text] [Related]
5. Exposure-response analyses of tigecycline tolerability in healthy subjects.
Passarell J; Ludwig E; Liolios K; Meagher AK; Grasela TH; Babinchak T; Ellis-Grosse EJ
Diagn Microbiol Infect Dis; 2009 Oct; 65(2):123-9. PubMed ID: 19748422
[TBL] [Abstract][Full Text] [Related]
6. Tigecycline does not prolong corrected QT intervals in healthy subjects.
Korth-Bradley JM; McGovern PC; Salageanu J; Matschke K; Plotka A; Pawlak S
Antimicrob Agents Chemother; 2013 Apr; 57(4):1895-901. PubMed ID: 23403419
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis.
Korth-Bradley JM; Baird-Bellaire SJ; Patat AA; Troy SM; Böhmer GM; Gleiter CH; Buecheler R; Morgan MY
J Clin Pharmacol; 2011 Jan; 51(1):93-101. PubMed ID: 20308689
[TBL] [Abstract][Full Text] [Related]
8. Absence of an interaction between tigecycline and digoxin in healthy men.
Zimmerman JJ; Harper DM; Matschke K; Speth JL; Raible DG; Fruncillo RJ
Pharmacotherapy; 2007 Jun; 27(6):835-44. PubMed ID: 17542766
[TBL] [Abstract][Full Text] [Related]
9. Tigecycline: a glycylcycline antimicrobial agent.
Doan TL; Fung HB; Mehta D; Riska PF
Clin Ther; 2006 Aug; 28(8):1079-1106. PubMed ID: 16982286
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.
Rubino CM; Bhavnani SM; Forrest A; Dukart G; Dartois N; Cooper A; Korth-Bradley J; Ambrose PG
Antimicrob Agents Chemother; 2012 Jan; 56(1):130-6. PubMed ID: 21968360
[TBL] [Abstract][Full Text] [Related]
11. Metabolism, excretion, and pharmacokinetics of [14C]tigecycline, a first-in-class glycylcycline antibiotic, after intravenous infusion to healthy male subjects.
Hoffmann M; DeMaio W; Jordan RA; Talaat R; Harper D; Speth J; Scatina J
Drug Metab Dispos; 2007 Sep; 35(9):1543-53. PubMed ID: 17537869
[TBL] [Abstract][Full Text] [Related]
12. Results of a multicenter, randomized, open-label efficacy and safety study of two doses of tigecycline for complicated skin and skin-structure infections in hospitalized patients.
Postier RG; Green SL; Klein SR; Ellis-Grosse EJ; Loh E;
Clin Ther; 2004 May; 26(5):704-14. PubMed ID: 15220014
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects.
Gotfried MH; Horn K; Garrity-Ryan L; Villano S; Tzanis E; Chitra S; Manley A; Tanaka SK; Rodvold KA
Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28696233
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study.
Purdy J; Jouve S; Yan JL; Balter I; Dartois N; Cooper CA; Korth-Bradley J
Clin Ther; 2012 Feb; 34(2):496-507.e1. PubMed ID: 22249106
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects.
Tianmei S; Knadler MP; Lim MT; Yeo KP; Teng L; Liang S; Pan AX; Lobo ED
Clin Pharmacokinet; 2007; 46(9):767-75. PubMed ID: 17713974
[TBL] [Abstract][Full Text] [Related]
16. Use of Monte Carlo simulation to evaluate the efficacy of tigecycline and minocycline for the treatment of pneumonia due to carbapenemase-producing Klebsiella pneumoniae.
Ni W; Li G; Zhao J; Cui J; Wang R; Gao Z; Liu Y
Infect Dis (Lond); 2018 Jul; 50(7):507-513. PubMed ID: 29316830
[TBL] [Abstract][Full Text] [Related]
17. Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.
Guo B; Wu X; Zhang Y; Shi Y; Yu J; Cao G; Zhang J
Clin Drug Investig; 2012 Jul; 32(7):475-86. PubMed ID: 22650326
[TBL] [Abstract][Full Text] [Related]
18. A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744].
Oliva ME; Rekha A; Yellin A; Pasternak J; Campos M; Rose GM; Babinchak T; Ellis-Grosse EJ; Loh E;
BMC Infect Dis; 2005 Oct; 5():88. PubMed ID: 16236177
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
20. Serum and urine pharmacokinetics of tigecycline in obese class III and normal weight adults.
Pai MP
J Antimicrob Chemother; 2014 Jan; 69(1):190-9. PubMed ID: 23883872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
